Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice

•Treatment with mitoxantrone once a week caused a dilated cardiomyopathy in mice.•Treatment with mitoxantrone once a week caused a large loss of body weight in mice.•Co-treatment with PACAP38 reduced the mitoxantrone-induced dilated cardiomyopathy.•Co-treatment with PACAP38 reduced the mitoxantrone-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Peptides (New York, N.Y. : 1980) N.Y. : 1980), 2017-09, Vol.95, p.25-32
Hauptverfasser:	Subramaniam, Venkat, Chuang, Gin, Xia, Huijing, Burn, Brendan, Bradley, Jessica, Maderdrut, Jerome L., Coy, David H., Varner, Kurt J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Blood cancer Cardioprotection Cardiotoxicity - drug therapy Cardiotoxicity - pathology Cell Line, Tumor Chemotherapy Disease Models, Animal Heart Injuries - chemically induced Heart Injuries - drug therapy Heart Injuries - pathology Humans Mice Mitoxantrone - adverse effects Mitoxantrone - therapeutic use Multiple sclerosis Neoplasms - complications Neoplasms - drug therapy Neoplasms - pathology Pituitary adenylate cyclase-activating polypeptide Pituitary Adenylate Cyclase-Activating Polypeptide - administration & dosage Protective Agents - administration & dosage Vasoactive intestinal peptide Ventricular Dysfunction, Left - chemically induced Ventricular Dysfunction, Left - drug therapy Ventricular Dysfunction, Left - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!